Legal Requirements

Legal Requirements 1. Under the statutory authority, conditions listed on the RUSP will be included in the comprehensive newborn screening program within three (3) years after being added to the RUSP and adopt any rules and regulations necessary to accomplish the program. a. If any RUSP-listed conditions are not added to the comprehensive newborn screening program within three (3) years, a report on the status and reasons for the delay will be submitted to the House and Senate Public Health Committees once a year after the three-year period. 2. Under the statutory authority, a list of each of the conditions included in the comprehensive newborn screening program and made available to physicians and other health care providers who are required to provide for newborn screening testing under Section 41-21-203. 3. Under the statutory authority, informational materials about newborn screening tests will be available for use by physicians and other health care providers to inform pregnant women and parents. 4. Under the statutory authority, ongoing epidemiologic surveillance of the comprehensive newborn screening program will be used determine the efficacy and cost effectiveness of screening newborn infants. 5. Under the statutory authority, the physician attending a newborn child, or the persons attending a newborn child who was not attended by a physician, is held responsible for ensuring that the child is tested for the newborn screening tests as described in these rules and regulations. State law exempts from these tests any child whose parents object thereto on the grounds that such tests conflict with their religious practices or tenets. 6. Under the statutory authority, screening for congenital hypothyroidism (TSH), phenylketonuria (PKU), hemoglobinopathies (Hgb), congenital adrenal hyperplasia (CAH), and galactosemia (GAL) will be conducted statewide. Screening for the following conditions, as determined and specified by the State Board of Health, will also be conducted: a. 2-Methylbutyryl-CoA Dehydrogenase Deficiency b. 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG) c. 3-Methylcrotonyl-CoA Carboxylase Deficiency (3MCC Def) d. 3-Methylglutaconyl-CoA Hydratase Deficiency e. 5-Oxoprolinuria (Pyroglutamic aciduria) f. Argininemia g. Argininosuccinic Aciduria (ASA Lyase Deficiency) h. Biotinidase Deficiency i. Carbamoylphosphate Synthetase Deficiency (CPS Deficiency) j. Carnitine Palmitoyltransferase I Deficiency (CPT I) k. Carnitine Palmitoyltransferase II Deficiency (CPT II) l. Carnitine/Acylcarnitine Translocase Deficiency (Translocase) m. Citrullinemia (ASA Synthetase Deficiency) n. Critical Congenital Heart Defects (CCHD) - Under the statutory authority, all licensed hospitals and other state licensed birthing facilities must test every newborn for CCHD statewide. All CCHD screenings must be performed prior to discharge and in accordance with current standards of care. Screening results must be reported to the Mississippi State Department of Health Newborn Screening Program. (Point of care testing which does not require blood) o. Cystic Fibrosis (CF) p. Glutaric Aciduria Type I (GA I) q. Homocystinuria r. Hyperammoninemia, Hyperornithinemia, Homocitrullinemia Syndrome (HHH) s. Hypermethioninemia t. Isobutyryl-CoA Dehydrogenase Deficiency u. Isovaleric Acidemia (IVA) v. Long-Chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD) w. Malonic Aciduria x. Maple Syrup Urine Disease (MSUD) y. Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD) z. Methylmalonic Acidemia (MMA) aa. Mitochondrial Acetoacetyl-CoA Thiolase Deficiency bb. Mucopolysaccharidosis I (MPS1) cc. Multiple Acyl-CoA Dehydrogenase Deficiency (MADD or GA II) dd. Multiple CoA Carboxylase Deficiency ee. Pompe ff. Propionic Acidemia (PPA) gg. Severe Combined Immunodeficiency (SCID) hh. Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD) ii. Short-Chain Hydroxy Acyl-CoA Dehydrogenase Deficiency (SCHAD) jj. Spinal Muscular Atrophy (SMA) kk. Trifunctional Protein Deficiency (TFP Deficiency) ll. Tyrosinemia Type I (TYR I) mm. Tyrosinemia Type II (TYR II) nn. Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD) oo. X-linked adrenoleukodystrophy (X-ALD) (starts July 1, 2023) pp. Cystic Fibrosis (338) qq. Guanidinoacetate Methyltransferase Deficiency (GAMT) rr. Infantile Globoid Cell Leukodystrophy ss. Mucopolysaccharidosis Type I + Fuller tt. Mucopolysaccharidosis Type II+ Fuller.